A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury
Study Overview The clinical trial investigated the efficacy of MLC901, also known as NeuroAiD II, in addressing cognitive deficits resulting […]
